Non-interventional, Retrospective, Multi-center Study to Evaluate Non-motor Symptoms in Advanced Parkinson Disease (PD) Patients Already Treated With Rotigotine (RETO-PD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01504529|
Recruitment Status : Completed
First Posted : January 5, 2012
Last Update Posted : April 15, 2013
This is an observational, non-interventional and retrospective study in patients with advanced PD who have been treated with Rotigotine (Neupro®) as prescribed by physicians according to usual clinical practice in Spain.
The Primary Objective will be to evaluate Non-Motor Symptoms (NMS) in advanced PD patients who have been treated with Rotigotine for at least 6 months.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||391 participants|
|Official Title:||Non-Interventional, Retrospective, Multi-center Study to Evaluate Non-Motor Symptoms in Advanced PD Patients Already Treated With Rotigotine|
|Study Start Date :||September 2011|
|Primary Completion Date :||December 2012|
|Study Completion Date :||December 2012|
Data from patients with advanced PD who have been treated with Rotigotine (Neupro®) for at least the previous 6 months as prescribed by physicians according to usual clinical practice in Spain, will be retrospectively collected.
- Change from Baseline to Month 6 in Non-Motor Symptoms (NMS) as assessed by the Parkinson's Disease Non-Motor Symptoms Questionnaire (PDNMS-Q) [ Time Frame: From Baseline to Month 6 ]
- Change from Baseline to Month 6 in Unified Parkinson's Disease Rating Scale (UPDRS) Part III [ Time Frame: From Baseline to Month 6 ]
- Change from Baseline to Month 6 in Hoehn & Yahr stage [ Time Frame: From Baseline to Month 6 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01504529
Show 59 Study Locations
|Study Director:||UCB Clinical Trial Call Center||+1 877 822 9493 (UCB)|